Coya Therapeutics, Inc. (COYA) shareholders
Close on Nov 17, 2026Market cap $70.84MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dr. Reddy's Laboratories Limited Joint filing with Dr. Reddy's Laboratories, Inc. (9.70%), Dr. Reddy's Laboratories SA (9.70%) | 2,272,727 | 9.70% | 13G (passive) | Jan 30, 2026 |
| DME Advisors GP, L.L.C. Joint filing with Einhorn David (9.90%), DME Capital Management, LP (7.60%) | 1,651,440 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| David Einhorn Joint filing with DME Advisors GP, LLC (5.80%) | 1,274,026 | 8.80% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COYA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| DME Capital Management, LP | 2,335,540 | 9.96% | $13.66M | – | 0.35% |
| Vanguard Capital Management LLC | 842,220 | 3.59% | $4.93M | −2,693 | 0.00% |
| Alyeska Investment Group, L.P. | 800,000 | 3.41% | $4.68M | – | 0.01% |
| AIGH Capital Management LLC | 631,912 | 2.69% | $3.70M | −343,492 | 0.23% |
| CM Management, LLC | 400,000 | 1.71% | $2.34M | +25,000 | 1.56% |
| Private Management Group Inc | 384,217 | 1.64% | $2.25M | +15,121 | 0.06% |
| Marshall Wace, Llp | 249,793 | 1.06% | $1.46M | +24,001 | 0.00% |
| Geode Capital Management, LLC | 228,243 | 0.97% | $1.34M | −5,159 | 0.00% |
| Renaissance Technologies LLC | 192,986 | 0.82% | $1.13M | +89,022 | 0.00% |
| Prosight Management, LP | 170,000 | 0.72% | $994.50K | −250,360 | 0.17% |
| Dimensional Fund Advisors LP | 155,917 | 0.66% | $913.04K | +59,998 | 0.00% |
| Vanguard Fiduciary Trust Co | 129,551 | 0.55% | $757.87K | −10,335 | 0.00% |
| Jones Financial Companies Lllp | 110,910 | 0.47% | $610.01K | +65,950 | 0.00% |
| BlackRock, Inc. | 102,408 | 0.44% | $599.09K | +19,639 | 0.00% |
| Prelude Capital Management, LLC | 101,330 | 0.43% | $592.78K | – | 0.04% |
| JBF Capital, Inc. | 100,006 | 0.43% | $585.04K | – | 0.08% |
| Royal Bank of Canada | 93,414 | 0.40% | $546.00K | +80,022 | 0.00% |
| Morgan Stanley | 82,106 | 0.35% | $480.32K | −3,594 | 0.00% |
| State Street Corp | 79,813 | 0.34% | $466.91K | – | 0.00% |
| Susquehanna International Group, Llp | 61,006 | 0.26% | $356.89K | +21,690 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 54 | 8M | 33.1% | 5 / 14 | 16 / 7 | 0M | 1M |
| Q1 2026 | 56 | 8M | 34.6% | 12 / 20 | 11 / 12 | 2M | 1M |
| Q4 2025 | 58 | 8M | 33.8% | 29 / 19 | 5 / 7 | 4M | 0M |
| Q3 2025 | 36 | 5M | 20.3% | 7 / 11 | 7 / 4 | 0M | 0M |
| Q2 2025 | 33 | 4M | 19.2% | 7 / 11 | 7 / 0 | 0M | 0M |
| Q1 2025 | 26 | 5M | 19.9% | 5 / 10 | 4 / 5 | 0M | 0M |
| Q4 2024 | 26 | 4M | 18.9% | 8 / 11 | 5 / 1 | 1M | 0M |
| Q3 2024 | 19 | 3M | 14.1% | 3 / 3 | 6 / 2 | 0M | 0M |
| Q2 2024 | 19 | 3M | 13.9% | 4 / 4 | 7 / 4 | 0M | 0M |
| Q1 2024 | 19 | 3M | 14.2% | 4 / 9 | 3 / 4 | 2M | 0M |
| Q4 2023 | 21 | 3M | 12.0% | 6 / 10 | 2 / 0 | 1M | 0M |
| Q3 2023 | 15 | 1M | 6.0% | 4 / 7 | 3 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
20 funds held COYA in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of COYA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 601,117 | 2.56% | $3.52M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 219,955 | 0.94% | $1.29M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 108,636 | 0.46% | $523.63K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 75,558 | 0.32% | $316.59K | 0.00% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 65,909 | 0.28% | $385.57K | 0.03% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 37,158 | 0.16% | $155.69K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 33,438 | 0.14% | $161.17K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 24,066 | 0.10% | $116.00K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 14,892 | 0.06% | $71.78K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 13,107 | 0.06% | $54.92K | 0.00% | Jul 31, 2026 |
| Vanguard Balanced Index Fund | 10,902 | 0.05% | $63.78K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 10,246 | 0.04% | $59.94K | 0.00% | Jun 30, 2026 |
| Schwab Total Stock Market Index Fund | 10,000 | 0.04% | $41.90K | 0.00% | Jul 31, 2026 |
| Dimensional US Vector Equity ETF | 4,793 | 0.02% | $20.08K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 4,435 | 0.02% | $25.94K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Howard Berman | Executive Chairman, Director | 949,338 | 4.05% | Jan 26, 2026 |
| Arun Swaminathan | Chief Executive Officer, Director | 10,000 | 0.04% | Jan 26, 2026 |
| David S. Snyder | Chief Financial Officer | 8,800 | 0.04% | Jan 26, 2026 |
| Fred Grossman | Chief Medical Officer | 2,710 | 0.01% | Jan 26, 2026 |
| Mark H. Pavao | Director | – | – | Apr 9, 2026 |
| Ann Lee | Director | 33,958 | 0.14% | Jan 6, 2026 |
| Wilbur L. Ross Jr | Director | 165,016 | 0.70% | Jan 6, 2026 |
| Dieter Weinand | Director | – | – | Jan 6, 2026 |
| Dov A. Goldstein Md | Director | 27,557 | 0.12% | Jan 6, 2026 |
| Anabella Villalobos | Director | 10,000 | 0.04% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dov A. Goldstein Md Director | Aug 18, 2025 | Option exercise | +17,557 | $1.09 | $19.14K | 27,557 |
| David S. Snyder Chief Financial Officer | Nov 14, 2024 | Buy | +1,800 | $7.19 | $12.94K | 8,800 |
| Arun Swaminathan Chief Executive Officer, Director | Nov 13, 2024 | Buy | +5,000 | $7.36 | $36.80K | 10,000 |
| Arun Swaminathan Chief Executive Officer, Director | Nov 11, 2024 | Buy | +5,000 | $7.34 | $36.70K | 5,000 |
| Fred Grossman Chief Medical Officer | Nov 11, 2024 | Buy | +2,710 | $7.37 | $19.97K | 2,710 |
| Ann Lee Director | Aug 22, 2023 | Buy | +1,000 | $3.62 | $3.62K | 17,479 |
| Ann Lee Director | Jan 3, 2023 | Conversion | +6,479 | $4.00 | $25.92K | 16,479 |
| Ann Lee Director | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| Howard Berman Chief Executive Officer, Director, 10% owner | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| Dov A. Goldstein Md Director | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| David S. Snyder Chief Financial Officer | Jan 3, 2023 | Buy | +7,000 | – | – | 7,000 |
| Anabella Villalobos Director | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
| Hideki Garren Director | Jan 3, 2023 | Buy | +2,000 | – | – | 2,000 |
| Adrian Hepner Chief Medical Officer | Jan 3, 2023 | Buy | +10,000 | – | – | 10,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Coya Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,020 shares on Sep 24, 2026 over the last 90 days.
See a number that looks wrong?